Andy Joe Seelam

Dr. Andy Joe Seelam

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
LMLaura Montefusco
Laura Montefusco
MNMoufida Ben Nasr
Moufida Ben Nasr
FDFrancesca D’addio
Francesca D’addio
Cristian LoretelliCristian Loretelli
Cristian Loretelli
ARAntonio Rossi
Antonio Rossi
Paolo FiorinaPaolo Fiorina
Paolo Fiorina

22 December 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
Cristian LoretelliCristian Loretelli
Cristian Loretelli
AAAhmed Abdelsalam
Ahmed Abdelsalam
FDFrancesca D'Addio
Francesca D'Addio
MNMoufida Ben Nasr
Moufida Ben Nasr
EAEmma Assi
Emma Assi
Paolo FiorinaPaolo Fiorina
Paolo Fiorina
A substantial proportion of patients who have recovered from coronavirus disease-2019 (COVID-19) experience COVID-19–related symptoms even months after hospital discharge. We extensively immunologically characterized patients who recovered from COVID-19. In these patients, T cells were exhausted, with increased PD-1 + T cells, as compared with healthy controls. Plasma levels of IL-1 β , IL-1RA, and IL-8, among others, were also increased in patients who recovered from COVID-19. This altered immunophenotype was mirrored by a reduced ex vivo T cell response to both nonspecific and specific stimulation, revealing a dysfunctional status of T cells, including a poor response to SARS-CoV-2 antigens. Altered levels of plasma soluble PD-L1, as well as of PD1 promoter methylation and PD1 -targeting miR–15-5p, in CD8 + T cells were also observed, suggesting abnormal function of the PD-1/PD-L1 immune checkpoint axis. Notably, ex vivo blockade of PD-1 nearly normalized the aforementioned immunophenotype and restored T cell function, reverting the observed post–COVID-19 immune abnormalities; indeed, we also noted an increased T cell–mediated response to SARS-CoV-2 peptides. Finally, in a neutralization assay, PD-1 blockade did not alter the ability of T cells to neutralize SARS-CoV-2 spike pseudotyped lentivirus infection. Immune checkpoint blockade ameliorates post–COVID-19 immune abnormalities and stimulates an anti–SARS-CoV-2 immune response.

2 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
SUSimone Ummarino
Simone Ummarino
CHClinton Hausman
Clinton Hausman
GGGiulia Gaggi
Giulia Gaggi
LRLucrezia Rinaldi
Lucrezia Rinaldi
MBMahmoud Adel Bassal
Mahmoud Adel Bassal
ARAnnalisa Di Ruscio
Annalisa Di Ruscio
Nutritional intake impacts the human epigenome by directing epigenetic pathways in normal cell development via as yet unknown molecular mechanisms. Consequently, imbalance in the nutritional intake is able to dysregulate the epigenetic profile and drive cells towards malignant transformation. Here we present a novel epigenetic effect of the essential nutrient, NAD. We demonstrate that impairment of DNMT1 enzymatic activity by NAD-promoted ADP-ribosylation leads to demethylation and transcriptional activation of the CEBPA gene, suggesting the existence of an unknown NAD-controlled region within the locus. In addition to the molecular events, NAD- treated cells exhibit significant morphological and phenotypical changes that correspond to myeloid differentiation. Collectively, these results delineate a novel role for NAD in cell differentiation, and indicate novel nutri-epigenetic strategies to regulate and control gene expression in human cells.

15 March 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MNMoufida Ben Nasr
Moufida Ben Nasr
VUVera Usuelli
Vera Usuelli
ASAndy Joe Seelam
Andy Joe Seelam
FDFrancesca D'Addio
Francesca D'Addio
RAReza Abdi
Reza Abdi
Paolo FiorinaPaolo Fiorina
Paolo Fiorina
Since they were discovered almost three decades ago, a subset of B cells denoted as regulatory B cells (Bregs) have elicited interest throughout the immunology community. Many investigators have sought to characterize their phenotype and to understand their function and immunosuppressive mechanisms. Indeed, studies in murine models have demonstrated that Bregs possess varied phenotypic markers and could be classified into different subsets whose action and pivotal role depend on the pathological condition or stimuli. Similar conclusions were drawn in clinical settings delineating an analogous Breg population phenotypically resembling the murine Bregs that ultimately may be associated with a state of tolerance. Recent studies suggested that Bregs may play a role in the onset of autoimmune diabetes. This review will focus on deciphering the different subclasses of Bregs, their emerging role in autoimmune diabetes, and their potential use as a cell-based therapeutic.

19 May 2026 in Circulation
Verified
Journal Article
Open access
YCYanjia Che
Yanjia Che
YYYuta Yamamura
Yuta Yamamura
SJSungwook Jung
Sungwook Jung
GSGianmarco Sabiu
Gianmarco Sabiu
SKShameer M. Kondengadan
Shameer M. Kondengadan
RAReza Abdi
Reza Abdi
BACKGROUND: The entrance of naive T cells into lymph nodes (LNs) is a crucial step for induction of heart transplant acceptance under costimulatory blockade. Specialized blood vessels within the LN known as high endothelial venules (HEVs) mediate this process. HEVs express a key glycoprotein containing 6-sulfo sialyl Lewis X, the binding site for L-selectin on the membrane of naive T cells. The proper formation of this carbohydrate requires sulfation by N-acetylglucosamine 6-O-sulfotransferases, particularly CHST4. Given the critical role of CHST4 in HEVs and transplant immunity, we aimed to develop a first-in-class antibody-drug conjugate (ADC) targeting the CHST4/HEV axis to deliver immunoregulatory therapeutics to LNs and promote long-term cardiac transplant survival. METHODS: We used CHST4 knockout mice and inducible diphtheria toxin receptor mouse models to investigate the role of CHST4 in HEV function during heart allograft transplantation. To assess the impact of CHST4 deficiency on heart transplant outcomes, we used fully major histocompatibility complex–mismatched and single major histocompatibility complex class II–mismatched models to study acute and chronic heart transplant rejection, respectively. We developed a first-in-class, dual-payload antibody-drug conjugate aimed at promoting regulatory T cells by conjugating rapamycin and tubastatin A to the HEV-targeting MHA112 antibody. The efficacy of this ADC was tested in murine heart allograft models. RESULTS: Loss of CHST4 expression by HEVs impaired the entry of naive T cells into LNs and consequently reduced regulatory T cell formation, thereby disrupting cardiac transplant acceptance under costimulatory blockade. Treatment with the HEV-targeted ADC carrying rapamycin and tubastatin A prolonged murine heart allograft survival and suppressed chronic rejection, a major barrier to long-term graft success. Mechanistically, this ADC enhanced regulatory T cell induction, reduced proinflammatory T cells within lymph nodes, and decreased immune cell infiltration in cardiac allografts, achieving these effects with substantially lower doses of rapamycin and tubastatin A compared with administration of the free drugs. CONCLUSIONS: Our findings uncover a key mechanistic role for CHST4 in HEVs in facilitating the regulatory T cell generation within the LN and promoting heart transplant acceptance. Moreover, we introduce a promising CHST4-based, HEV-targeted ADC therapy as a potential strategy to suppress heart transplant rejection.